Clinical Trial: TEP With 68-DOTANOC in Gastroenteropancreatic Neuroendocrine Tumors

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: Diagnostic, Prospective, Comparative, Multicentric Study of the PET / CT With 68Ga-DOTANOC Versus Conventional Imaging Procedures (octréoscan ® Scintigraphy and CT / MRI) in the Assessment o

Brief Summary:

Evaluation of the diagnostic performance of PET / CT with 68Ga-DOTANOC in Gastroenteropancreatic Neuroendocrine Tumors with comparison with other techniques used in routine clinical practice (octreoscan ® ; multiphase SPECT / CT, MRI or endoscopy).

Therapeutic impact and safety of PET / CT with 68Ga-DOTANOC will also be assessed. Expected results are a confirmation of the superiority of 68Ga-PET DOTANOC versus scintigraphy octreoscan ®, with a potential impact on the therapeutic management of patients.


Detailed Summary:
Sponsor: Nantes University Hospital

Current Primary Outcome: Detection of Gastroenteropancreatic Neuroendocrine Tumors lesions in the initial assessment or during the search of recurrence. [ Time Frame: 12 months ]

Reference to the gold standard (that will be obtained from the data of histology and / or follow-up imaging at least 12 months


Original Primary Outcome: Same as current

Current Secondary Outcome: Compare the diagnostic performance of PET / CT with 68Ga-DOTANOC with the standard process [ Time Frame: 12 months ]

Original Secondary Outcome: Same as current

Information By: Nantes University Hospital

Dates:
Date Received: November 13, 2012
Date Started: November 2012
Date Completion:
Last Updated: July 28, 2016
Last Verified: July 2016